Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis
The Journal of Pathology · 2023
DOI: 10.1002/path.6060 ↗At a glance
Journal article in The Journal of Pathology, 2023. Written by Jacqueline Fontugne and 13 co-authors. Institution: Institut Curie, CNRS, UMR144, Equipe labellisée Ligue Contre le Cancer, PSL Research University, Paris, France. Major MEDLINE topics: Urinary Bladder Neoplasms, Sarcoma, Soft Tissue Neoplasms, Carcinoma, Squamous Cell. Cited 25 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Marie Curie, Fondation ARC pour la Recherche sur le Cancer, Institut Curie.
Abstract (original language)
The aggressive basal/squamous (Ba/Sq) bladder cancer (BLCA) subtype is often diagnosed at the muscle‐invasive stage and can progress to the sarcomatoid variant. Identification of molecular changes occurring during progression from non‐muscle‐invasive BLCA (NMIBC) to Ba/Sq muscle‐invasive BLCA (MIBC) is thus challenging in human disease. We used the N ‐butyl‐ N ‐(4‐hydroxybutyl)‐nitrosamine (BBN) mouse model of Ba/Sq MIBC to study longitudinally the molecular changes leading to the Ba/Sq phenotype and to the sarcomatoid variant using IHC and microdissection followed by RNA‐seq at all stages of progression. A shift to the Ba/Sq phenotype started in early progression stages. Pathway analysis of gene clusters with coordinated expression changes revealed Shh signaling loss and a shift from fatty acid metabolism to glycolysis. An upregulated cluster, appearing early in carcinogenesis, showed relevance to human disease, identifying NMIBC patients at risk of progression. Similar to the human counterpart, sarcomatoid BBN tumors displayed a Ba/Sq phenotype and epithelial–mesenchymal transition (EMT) features. An EGFR/FGFR1 signaling switch occurred with sarcomatoid dedifferentiation and correlated with EMT. BLCA cell lines with high EMT were the most sensitive to FGFR1 knockout and resistant to EGFR knockout. Taken together, these findings provide insights into the underlying biology of Ba/Sq BLCA progression and sarcomatoid dedifferentiation with potential clinical implications. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institut Curie, CNRS, UMR144, Equipe labellisée Ligue Contre le Cancer, PSL Research University, Paris, France.
- Department of Pathology, Institut Curie, Saint-Cloud, France.
- Université Paris-Saclay, Université Versailles St-Quentin, Montigny-le-Bretonneux, France.
- Department of Genetics, Institut Curie, Paris, France.
- Genomics Core Facility, Translational Research Department, PSL Research University, Institut Curie, Paris, France.
- Department of Pathology, Institut Curie, Paris, France.
ORCID profiles: Jacqueline Fontugne, Yves Allory
Funding
- Marie Curie
- Fondation ARC pour la Recherche sur le Cancer
- Institut Curie
- Agence Nationale de la Recherche
Cite
APA
Fontugne, J., Wong, J., Cabel, L., Neyret-Kahn, H., Karboul, N., Maillé, P., Rapinat, A., Gentien, D., Nicolas, A., Baulande, S., Sibony, M., Bernard-Pierrot, I., Radvanyi, F., & Allory, Y. (2023). Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis. The Journal of Pathology. https://doi.org/10.1002/path.6060
Vancouver
Fontugne J, Wong J, Cabel L, Neyret-Kahn H, Karboul N, Maillé P, et al. Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis. The Journal of Pathology. 2023. doi:10.1002/path.6060
BibTeX
@article{Fontugne2023,
author = {Fontugne, Jacqueline and Wong, Jennifer and Cabel, Luc and Neyret-Kahn, Hélène and Karboul, Narjesse and Maillé, Pascale and Rapinat, Audrey and Gentien, David and Nicolas, André and Baulande, Sylvain and Sibony, Mathilde and Bernard-Pierrot, Isabelle and Radvanyi, François and Allory, Yves},
title = {Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis},
journal = {The Journal of Pathology},
year = {2023},
doi = {10.1002/path.6060}
}
EUVIMED